Antibody deficiencies can be either primary or secondary, leading to significant morbidity and mortality without appropriate management. Secondary antibody deficiency can be due to various diseases or iatrogenic causes, especially with the use of immunosuppressive agents such as B-cell depleting therapies. Unlike its primary counterpart, little is known regarding the management of secondary antibody deficiency and it remains an underappreciated entity. This is a growing concern with the growing numbers of patients on various immunosuppressant therapies and increasing survivors of autoimmune diseases and haematological malignancies. In this report, we review the diagnosis and management of secondary antibody deficiency, especially after ritu...
Hematological malignancies and immunochemotherapy are frequently associated with secondary cellular ...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
BACKGROUND: As the indications and use of rituximab continue to expand, the reports of long-term eff...
Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies. Primary antib...
<div><p>Secondary antibody deficiency can occur as a result of haematological malignancies or certai...
Primary antibody deficiencies (PAD) constitute the majority of all primary immunodeficiency diseases...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
Immunoglobulin therapy is the administration of human polyvalent IgG and represents the most effecti...
Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies. Primary antib...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
Rituximab, an anti-CD20 chimeric antibody, is the first monoclonal agent to be used in the therapy o...
Purpose of review Induction of lymphocyte depletion is increasingly used as a therapeutic strategy ...
The anti-CD20 B cell depleting monoclonal antibody rituximab is being used increasingly for autoimmu...
We describe a case of a 3-year-old male toddler with a history of severe and refractory warm antibod...
The anti-CD20 B cell depleting monoclonal antibody rituximab is being used increasingly for autoimmu...
Hematological malignancies and immunochemotherapy are frequently associated with secondary cellular ...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
BACKGROUND: As the indications and use of rituximab continue to expand, the reports of long-term eff...
Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies. Primary antib...
<div><p>Secondary antibody deficiency can occur as a result of haematological malignancies or certai...
Primary antibody deficiencies (PAD) constitute the majority of all primary immunodeficiency diseases...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
Immunoglobulin therapy is the administration of human polyvalent IgG and represents the most effecti...
Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies. Primary antib...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
Rituximab, an anti-CD20 chimeric antibody, is the first monoclonal agent to be used in the therapy o...
Purpose of review Induction of lymphocyte depletion is increasingly used as a therapeutic strategy ...
The anti-CD20 B cell depleting monoclonal antibody rituximab is being used increasingly for autoimmu...
We describe a case of a 3-year-old male toddler with a history of severe and refractory warm antibod...
The anti-CD20 B cell depleting monoclonal antibody rituximab is being used increasingly for autoimmu...
Hematological malignancies and immunochemotherapy are frequently associated with secondary cellular ...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
BACKGROUND: As the indications and use of rituximab continue to expand, the reports of long-term eff...